Financial Comparison
Abbott Laboratories vs Zimmer Biomet Holdings, Inc.
Click a ticker to view the full analysis.
In short
Abbott Laboratories is the more profitable of the two, keeping 14.7% of revenue as net profit against 8.6% for Zimmer Biomet Holdings, Inc. Abbott Laboratories trades at the higher trailing P/E (31.9× vs 21.6× for Zimmer Biomet Holdings, Inc.), so investors pay more for each dollar of its earnings. Fisclear flags 1 medium- or high-severity risk for Abbott Laboratories and 0 for Zimmer Biomet Holdings, Inc.
Based on filings for periods ending 30 Jun 2026 (ABT) and 30 Jun 2026 (ZBH) · Updated
FisclearScore Comparison
FisclearScore is a quantitative model. ABT shown solid · ZBH shown dashed. Not financial advice.
| Metric | ABT | ZBH |
|---|---|---|
| Price | $98.49 | $88.88 |
| Market Cap | $171.6B | $17.0B |
| P/E (TTM) | 31.9x | 21.6x |
| P/B | 3.3x | 1.3x |
| Beta | 0.58 | 0.48 |
| Div Yield | 2.48% | 1.04% |
| Revenue (TTM) | $44.3B | $8.2B |
| Net Income | $6.5B | $705M |
| Gross Margin | — | — |
| Risk Flags | 1 flag | — |
Related comparisons
Data sourced from SEC EDGAR, Yahoo Finance, and official exchange filings. For informational purposes only. Not financial advice.